Login to Your Account


Street a-twitter about Bluebird, too

Now that Celgene Corp. has made its $9 billion move to take over Juno Therapeutics Inc., advancing in the ever-hot CAR T-cell space, speculation has turned to the ultimate odds of dominance, eventual sales numbers if the CD19-targeting JCAR-017 wins FDA clearance.

more »


Opinion


Partners in Focus